BCR-ABL RTPCR (QUALITATIVE) (In Karad)

Detect the BCR-ABL fusion gene, commonly linked to leukemia, with Diagnopein’s BCR-ABL RTPCR (Qualitative) test. Our fast, reliable, and accurate testing helps guide effective trea

test
test
Report Availability
24 hours
₹ 3100 /-
Free Home Blood Collection
Book A Test

Your Health is Our Priority

Overview

The BCR-ABL RTPCR (Qualitative) test detects the BCR-ABL fusion gene, commonly associated with chronic myeloid leukemia (CML) and certain cases of acute lymphoblastic leukemia (ALL). Using Reverse Transcription Polymerase Chain Reaction (RTPCR) technology, the test determines whether the gene is present, helping doctors confirm diagnoses and guide treatment plans. Early detection is crucial for improving patient outcomes.

How the Test Works

The BCR-ABL RTPCR test analyzes genetic material from blood or bone marrow. Using Reverse Transcription Polymerase Chain Reaction (RTPCR) technology, it detects abnormal fusion transcripts produced by the BCR-ABL gene. A positive result indicates the gene is present, while a negative result suggests it is absent.

The procedure is fast, precise, and minimally invasive, making it a preferred choice for hematologists and oncologists in diagnosing leukemia.

 

Why It’s Important

Detecting the BCR-ABL fusion gene early can:

  1. Help confirm a diagnosis of CML or ALL.
  2. Guide personalized treatment options, including targeted therapies like tyrosine kinase inhibitors.
  3. Monitor disease progression or remission when combined with quantitative follow-up tests.

Early diagnosis through BCR-ABL RTPCR can significantly improve patient outcomes and reduce complications associated with delayed treatment.

Why Choose Diagnopein for BCR-ABL RTPCR (QUALITATIVE) Test?

  1. Accurate and Reliable: Certified labs ensure precise results.
  2. Fast Turnaround: Quick results for timely medical decisions.
  3. Safe Sample Collection: Hassle-free blood or bone marrow collection.
  4. Expert Guidance: Support to understand your results and next steps.

Talk to an Pathologist

  I HereBy Consent to receive calls/messagess from Diagnopein Pathology and its partners and override DND settings

faq image

Frequently Asked Questions

The test involves drawing a blood sample or obtaining a bone marrow aspirate, which is then analyzed in the laboratory using RT-PCR technology to detect the BCR-ABL fusion gene.

A positive result indicates the presence of the BCR-ABL fusion gene, confirming a diagnosis of chronic myeloid leukemia or acute lymphoblastic leukemia.

The test involves a standard blood draw or bone marrow aspiration, which may cause minor discomfort but is generally quick and well-tolerated.

Results are typically available within a few days, depending on laboratory processing times and demand.

BCR-ABL RTPCR (QUALITATIVE) Test in Shaniwar peth karad  |